[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 179
Citations 0
Correction
December 2018

Error in Figure 2

JAMA Oncol. 2018;4(12):1792. doi:10.1001/jamaoncol.2018.6227

In the Brief Report titled “Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial,”1 published online August 30, 2018, there was an error in Figure 2. The text and the overall survival data were correct, but the Kaplan-Meier curves and median values were incorrect. This article was corrected online.

References
1.
Gridelli  C, de Castro Carpeno  J, Dingemans  A-MC,  et al.  Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non–small cell lung cancer: the AvaALL randomized clinical trial [published online August 30, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.3486.Google Scholar
×